EP1799739A1 - Gele - Google Patents

Gele

Info

Publication number
EP1799739A1
EP1799739A1 EP05791328A EP05791328A EP1799739A1 EP 1799739 A1 EP1799739 A1 EP 1799739A1 EP 05791328 A EP05791328 A EP 05791328A EP 05791328 A EP05791328 A EP 05791328A EP 1799739 A1 EP1799739 A1 EP 1799739A1
Authority
EP
European Patent Office
Prior art keywords
gel according
formula
test
compound
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05791328A
Other languages
English (en)
French (fr)
Other versions
EP1799739A4 (de
EP1799739B1 (de
Inventor
Ajay Padsalgikar
Trang Thanh Nhan
Sriram Venkataramani
Mansour Mehrabi
Mark Bown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aortech International PLC
Original Assignee
Aortech Biomaterials Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905628A external-priority patent/AU2004905628A0/en
Application filed by Aortech Biomaterials Pty Ltd filed Critical Aortech Biomaterials Pty Ltd
Publication of EP1799739A1 publication Critical patent/EP1799739A1/de
Publication of EP1799739A4 publication Critical patent/EP1799739A4/de
Application granted granted Critical
Publication of EP1799739B1 publication Critical patent/EP1799739B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/46—Block-or graft-polymers containing polysiloxane sequences containing polyether sequences
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0838—Compounds with one or more Si-O-Si sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/2805—Compounds having only one group containing active hydrogen
    • C08G18/2815—Monohydroxy compounds
    • C08G18/283—Compounds containing ether groups, e.g. oxyalkylated monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/30—Low-molecular-weight compounds
    • C08G18/32—Polyhydroxy compounds; Polyamines; Hydroxyamines
    • C08G18/3271—Hydroxyamines
    • C08G18/3278—Hydroxyamines containing at least three hydroxy groups
    • C08G18/3284—Hydroxyamines containing at least three hydroxy groups containing four hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/61—Polysiloxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/442—Block-or graft-polymers containing polysiloxane sequences containing vinyl polymer sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/445—Block-or graft-polymers containing polysiloxane sequences containing polyester sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/458—Block-or graft-polymers containing polysiloxane sequences containing polyurethane sequences

Definitions

  • the present invention relates to silicon-containing biostable gels and processes for their preparation.
  • the gels possess properties which make them useful in the manufacture and repair of biomaterials and medical devices, articles or implants, in particular the manufacture of soft tissue implants such as breast implants and the repair of orthopaedic joints such as spinal discs.
  • Polymer gels are semi-solid systems that respond in a liquid like fashion under certain circumstances but their molecules do not have motion that is independent of each other, hence they behave like solids in other circumstances.
  • Gels can be synthesised as physical gels where a cross-linked network is swelled by a non reactive liquid. Without the presence of this swelling medium the cross- linked network would be a solid.
  • Silicone gels currently used in breast implants are physical gels where a cross- linked polydimethylsiloxane (PDMS) system is swollen by a non reactive, low molecular weight PDMS. These gels are inherently prone to leakage of the low molecular weight liquid PDMS and contain heavy metal catalysts such as platinum and tin which can leach out of the implant in an in-vivo situation.
  • PDMS cross- linked polydimethylsiloxane
  • Hydrogels are other examples of physical gels, where hydrophilic groups in the cross-linked network can attract water molecules and are swollen by them.
  • a physical gel the parts by weight of the swelling medium can be as high as 90%. This swelling medium can be extracted out of the gel by most solvents and biological fluids.
  • a gel comprising at least one silicon-containing biostable polymer having an average functionality in the range of from 2 to 5, preferably from 2.05 to 3.5, more preferably from 2.1 to 3.25.
  • the biostable polymer is preferably a polyurethane or polyurethane urea.
  • the polyurethane or polyurethane urea is the reaction product of:
  • polyurethane or polyurethane urea defined above may also be the reaction product of:
  • the present invention also provides a process for preparing the polyurethane polyurethane urea defined above which comprises the step of:
  • the process for preparing the polyurethane or polyurethane urea defined above comprises the steps of:
  • the process for preparing the polyurethane or polyurethane urea defined above comprises the steps of: (i) mixing components (a) and (b) and (c) (when present) as defined above with a photoinitiater; and
  • R x and R 2 are independently selected from C ⁇ - ⁇ alkylene optionally substituted with OH or NR 1 R" in which R 1 and R' ' are independently selected from H, CO 2 H and Ci_ 6 alkyl; - A -
  • R 3 to R 8 are independently selected from C 1-6 alkyl and C 1 - S alkylene which may be optionally interrupted by 0 and optionally substituted with OH or NR 1 R" in which R' and R' ' are as defined above;
  • R 9 is Ci-4 alkyl
  • Ri o is optionally substituted C1-4 alkyl or
  • R 1 and R 9 are as defined above; x is 5 to 30; y is 1 to 10; and n is 1 to 10.
  • the present invention further provides a process for the preparation of the silicon-containing polyol of formula (I) or (II) defined above which comprises the steps of:
  • step (C) (ii) subjecting the product of step (i) to hydrosilation.
  • the gels of the present invention possess visco- elastic properties and have a natural tissue feel to suit, for example, soft tissue implant gel applications such as breast implants. These gels also have a low level of extractables preferably less than 35%, more preferably less than 30%, most preferably less than 21% based on the total weight of the gel.
  • the present invention also provides a biomaterial, device, article or implant which is wholly or partly composed of the gels defined above.
  • the present invention further provides a filler material for a medical implant which comprises the gel defined above.
  • the gel of the present invention which comprises at least one silicon containing biostable polymer is a chemical gel.
  • a cross-linked network is formulated such that the reactive groups are in a perfect balance then, during the course of the reaction, the network begins to vitrify and ends up being a hard solid. If the reaction is not allowed to go to completion by creating an imbalance in the reactive groups, then an off- stoichiometric system occurs which is capable of gelation. Thus, one reactive group is in excess and remains incompletely reacted. This excess amount acts similar to the non-reactive swelling medium in physical gels. However, usually lower amounts of unreacted material, in comparison to the swelling agents, can be formulated to achieve a similar effect to a physical gel and that, in turn, implies lower extractable species.
  • the level of extractables in the gel of the present invention is preferably less than 35%, more preferably less than 30%, most preferably less than 21% based on the total weight of the gel.
  • extractables refers to the unreacted portion of the gel which is generally fluid and free to migrate out of the gel at body temperature of 38 0 C and more specifically, refers to the unreacted fluid portion of a gel which is extracted by organic solvents at temperatures in the range from 20 0 C to 40 0 C.
  • biostable refers to the stability of the polymer when in contact with cells and/or bodily fluids of living animals or humans.
  • average functionality refers to the average number of functional groups per monomer for all types of monomer molecules and is defined by the following formula:
  • ni is number of molecules of monomer i with functionality groups f ⁇ .
  • the average functionality of the gel is in the range of from 2.05 to 3.5, more preferably from 2.1 to 3.25.
  • the biostable polymer may be a polyurethane, polyurethane urea, polyolefin, polyester, polytetrafluroethylene or polymethacrylate such as poly(methylmethacrylate) .
  • the biostable polymer is a polyurethane or polyurethane urea.
  • the polyurethane or polyurethane urea may be formed from a silicon-containing polyol or polyamine having 1 or more functional groups (a) , a polyisocyanate (b) and optionally a non-silicon containing compound having 1 or more functional groups (c) .
  • the functional groups of components (a) and (c) may be any types of groups which can react with isocyanate and are preferably selected from OH, NR 1 R 1 ' in which R 1 and R 1 ' are the same or different and selected from H, CO 2 H and Ci- 6 alkyl, preferably H and Ci_ 4 alkyl or are groups capable of activation by free radical initiation such as double or triple bonds.
  • the silicon-containing polyol or polyamine (a) can have 1 or more functional groups provided that the average functionality of the biostable polymer is in the range from 1 to 5.
  • Suitable silicon-containing polyols or polyamines (a) include compounds of the formula (I) or (II) defined above, polysiloxanes or silicon-containing polycarbonates.
  • the molecular weight of the compounds of formula (I) is preferably from 400 to 5000. It will be understood that the molecular weight values referred to herein are "number average molecular weights" .
  • the molecular weight of the compounds of formula (II) is preferably from 1000 to 5000.
  • the polysiloxane may be hydroxy or amine terminated.
  • Suitable polysiloxane macrodiols or macrodiamines may be represented by the formula (III) :
  • a and A 1 are OH or NHR wherein R is H or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical, preferably Ci-s alkyl, more preferably Ci- 4 alkyl;
  • R-ii/ R-12, Ri3 and R 14 are the same or different and selected from hydrogen or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical; Ri 5 and R 16 are the same or different and selected from an optionally substituted straight chain, branched or cyclic alkylene, alkenylene, alkynylene or heterocyclic divalent radical; and p is an integer of 1 or greater.
  • Preferred polysiloxanes are polysiloxane macrodiols which are polymers of the formula (III) wherein A and A' are hydroxy.
  • a preferred polysiloxane is PDMS which is a compound of formula (III) in which A and A 1 are hydroxyl, Rn to Ri 4 are methyl and Ri 5 and Ri 6 are as defined above.
  • PDMS is a compound of formula (III) in which A and A 1 are hydroxyl, Rn to Ri 4 are methyl and Ri 5 and Ri 6 are as defined above.
  • Ri 5 and Ri 6 are the same or different and selected from propylene, butylene, pentylene, hexylene, ethoxypropyl (-CH 2 CH 2 OCH 2 CH 2 CH 2 -), propoxypropyl and butoxypropyl.
  • silicon-containing diols of the formula (III) are 1, 3-bis (4-hydroxybutyl) tetramethyl disiloxane (BHTD) (compound of formula (III) in which A and A 1 are OH, Rn, Ri2, Ri 3 and R i4 are methyl, R i5 and R i6 are butyl and R i7 is O), 1,4-bis (3-hydroxypropyl) tetramethyl disilylethylene (compound of formula (III) in which A and A 1 are OH, Ri, R12, Ri 3 and Ri 4 are methyl, Ri 5 and Ri 6 are propyl and R 17 is ethylene) and 1-4-bis(3-hydroxypropyl) tetramethyl disiloxane, more preferably BHTD.
  • BHTD 1, 3-bis (4-hydroxybutyl) tetramethyl disiloxane
  • the polysiloxanes may be obtained as commercially available products such as X-22-160AS from Shin Etsu in Japan or prepared according to known procedures.
  • the preferred molecular weight range of the polysiloxane macrodiol is 200 to 6000, more preferably from 200 to 5000.
  • polysiloxanes are polysiloxane macrodiamines which are polymers of the formula (III) wherein A is NH 2 , such as, for example, amino-terminated PDMS.
  • Suitable silicon-containing polycarbonates include those described in International Patent Publication No. WO 98/54242, the entire content of which is incorporated herein by reference.
  • a preferred silicon-containing polycarbonate has the formula (IV) :
  • Rii/ Ri2/ Ri3, Ri4 and Ri 5 are as defined in formula (III) above,-
  • R 1S is an optionally substituted straight chain, branched or cyclic alkylene, alkenylene, alkynylene or heterocyclic divalent radical;
  • R 17 is a divalent linking group, preferably O, S or NRi 8 ; Ri 8 and Ri 9 are same or different and selected from hydrogen or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon divalent radical;
  • a and A 1 are as defined in formula (III) above; m, y and z are integers of 0 or more; and x is an integer of 0 or more.
  • z is an integer of 0 to 50 and x is an integer of 1 to 50.
  • Suitable values for m include 0 to 20, more preferably 0 to 10.
  • Preferred values for y are 0 to 10, more preferably 0 to 2.
  • a preferred silicon-containing polycarbonate is a compound of the formula (IV) in which A and A' are hydroxyl.
  • Particularly preferred silicon-containing polycarbonate macrodiols are compounds of the formula (IV) in which A and A' are hydroxyl, Rn, Ri 2 , R 13 and R i4 are methyl, Ri 8 is ethyl, R X9 is hexyl, R X5 and R x6 are propyl or Ri 4 butyl and R i7 is 0 or -CH 2 -CH 2 -,more preferably R 5 and Ri 6 are propyl when R 17 is 0 and Ri 5 and R 16 are butyl when Ri 7 is -CH 2 -CH 2 -.
  • the preferred molecular weight range of the silicon-based polycarbonate macrodiol is from 400 to 5000, more preferably from 400 to 2000.
  • polyisocyanate refers to di or higher isocyanates such as polymeric 4,4 ' -diphenylmethane diisocyanate (MDI) .
  • the polyisocyanate is preferably a diisocyanate which may be aliphatic or aromatic diisocyanates such as, for example MDI, methylene ⁇ biscyclohexyl diisocyanate (Hi 2 MDI) , p-phenylene diisocyanate (p-PDI) , trans-eyelohexane-1, 4-diisocyanate (CHDI) , 1,6-diisocyanatohexane (DICH) , 1, 5-diisocyanatonaphthalene (NDI) , para-tetramethylxylenediisocyanate (p-TMXDI) , meta-tetramethylxylene diisocyanate (m-TMXDI) , 2,4-toluene diisocyan
  • polyethers and polycarbonates may contain hydroxy or amine functional groups.
  • Suitable polyether macrodiols and macrodiamines include those represented by the formula (V)
  • a and A 1 are as defined in formula (III) above OH or NHR wherein R is H or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical, preferably C 1-6 alkyl, more preferably Q L - 4 alkyl; m is an integer of 4 or more, preferably 5 to 18; and n is an integer of 2 to 50.
  • Polyether macrodiols of formula (V) wherein m is 5 or higher such as polyhexamethylene oxide (PHMO) , polyheptamethylene oxide, polyoctamethylene oxide (POMO) and polydecamethylene oxide (PDMO) are preferred over the conventional polytetramethylene oxide (PTMO) .
  • PHMO polyhexamethylene oxide
  • POMO polyoctamethylene oxide
  • PDMO polydecamethylene oxide
  • the more preferred macrodiols and their preparation are described in Gunatillake et al 3 and US 5403912.
  • Polyethers such as PHMO described in these references are particularly useful as they are more hydrophobic than PTMO and more compatible with polysiloxane macrodiols.
  • tri- and tetra- functional polyethers examples include Voranol which is a polyether triol resulting from a base catlysed reaction of glycerol and propylene oxide and N,N,N 1 -tri(2-hydroxypropyl) -N 1 -hydroxyethyl ethylene diamine (Poly Q) , respectively.
  • the preferred molecular weight range of the polyether is from 200 to 5000, more preferably from 200 to 2000.
  • Suitable polycarbonate macrodiols include poly(alkylene carbonates) such as poly(hexamethylene carbonate) and poly(decamethylene carbonate) ; polycarbonates prepared by reacting alkylene carbonate with alkanediols for example 1,4-butanediol, 1,10- decanediol (DD), 1, 6-hexanediol (HD) and/or 2,2-diethyl 1,3-propanediol (DEPD) ; and silicon based polycarbonates prepared by reacting alkylene carbonate with l,3-bis(4- hydrpxybutyl) -1, 1, 3,3-tetramethyldisiloxane (BHTD) and/or alkanediols.
  • alkanediols 1,4-butanediol, 1,10- decanediol (DD), 1, 6-hexanediol (HD) and/or 2,2-diethyl 1,3-
  • polyether and polycarbonate macrodiols may be in the form of a mixture or a copolymer.
  • An example of a suitable copolymer is a copoly(ether carbonate) macrodiol represented by the formula (VI)
  • Ri and R 2 are the same or different and selected from an optionally substituted straight chain, branched or cyclic alkylene, alkenylene, alkynylene or heterocyclic divalent radical; and p and q are integers of 1 to 20.
  • p and q are integers of 1 to 20.
  • components (a) and (c) may be a combination of silicon-containing polyols and non-silicon containing polyols having different amounts of functional groups.
  • component (c) may contain a combination of a tri-functional polyether and a tetra- functional polyether.
  • the components (a) , (b) and (c) are preferably mixed so that the NCO/OH or NH 2 ratio is less than 1, more preferably from 0.4 to 0.7 so as to provide the appropriate rheological response.
  • the gel is a polyurethane urea which is the reaction product of:
  • alkylene is a divalent radical equivalent of the term “alkyl” .
  • the two bonds connecting the alkylene to the adjacent groups may come from the same carbon atom or difference carbon atoms in the divalent radical.
  • the "hydrocarbon radical” may include alkyl, alkenyl, alkynyl, aryl or heterocyclyl radicals.
  • alkyl denotes straight chain, branched or mono- or poly-cyclic alkyl, preferably C 1 -I 2 alkyl or cycloalkyl, more preferably Ci_ 6 alkyl, most preferably Ci. 4 alkyl.
  • straight chain and branched alkyl examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, amyl, isoamyl, sec-amyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, pentyl, neopentyl, hexyl, 4-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl,
  • 6-methylheptyl 1-methylheptyl, 1, 1,3, 3-tetramethylbutyl, nonyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-methyloctyl, 1-, 2-, 3-, 4- or 5-ethylheptyl, 1-, 2- or 3-propylhexyl, decyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- and 8-methylnonyl, 1-, 2-, 3-, 4-, 5- or 6-ethyloctyl, 1-, 2-, 3- or 4-propylheptyl, undecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-methyldecyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-ethylnonyl, 1-, 2-, 3-, 4- or 5-propyloctyl, 1-, 2- or 3-butylheptyl, 1-pentylhexyl, dodecyl, 1-, 2-, 3-, 4-, 5-, 6-,
  • cyclic alkyl examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl and the like.
  • alkenyl denotes groups formed from straight chain, branched or mono- or poly-cyclic hydrocarbon groups having at least one double bond, preferably C 2 -I 2 alkenyl, more preferably C 2 _ 6 alkenyl.
  • the alkenyl group may have E or Z stereochemistry where applicable.
  • alkenyl examples include vinyl, allyl, 1-methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl, 1-heptenyl, 3- heptenyl, 1-octenyl, cyclooctenyl, 1-nonenyl, 2-nonenyl,
  • 3-nonenyl 1-decenyl, 3-decenyl, 1,3-butadienyl, 1,4-pentadienyl, 1,3- cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, 1, 3-cycloheptadienyl, 1,3, 5-cycloheptatrienyl, 1,3, 5,7- (cycloocta-tetraenyl) and the like.
  • alkynyl denotes groups formed from straight chain, branched, or mono- or poly-cyclic hydrocarbon groups having at least one triple bond.
  • alkynyl include ethynyl, 1-propynyl, 1- and 2-butynyl, 2-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 10-undecynyl, 4-ethyl-l-octyn-3-yl, 7-dodecynyl,
  • aryl denotes single, polynuclear, conjugated and fused residues of aromatic hydrocarbons.
  • aryl include phenyl, biphenyl, terphenyl, quaterphenyl, phenoxyphenyl, naphthyl, tetrahydronaphthyl, anthracenyl, dihydroanthracenyl, benzanthracenyl, dibenzanthracenyl, phenanthrenyl and the like.
  • heterocyclyl denotes mono- or poly-cyclic heterocyclyl groups containing at least one heteroatom selected from nitrogen, sulphur and oxygen.
  • Suitable heterocyclyl groups include N-containing heterocyclic groups, such as, unsaturated 3 to 6 membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl or tetrazolyl; saturated 3 to 6 membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, such as pyrrolidinyl, imidazolidinyl, piperidino or piperazinyl; unsaturated condensed heterocyclic groups containing 1 to 5 nitrogen atoms, such as, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl or tetrazolopyridazin
  • optionally substituted means that a group may or may not be further substituted with one or more groups selected from oxygen, nitrogen, sulphur, alkyl, alkenyl, alkynyl, aryl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, hydroxy, alkoxy, alkenyloxy, alkynyloxy, aryloxy, carboxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloalkynyloxy, haloaryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, azido, amino, alkylamino, alkenylamino, alkynylamino, arylamino, benzylamino, acyl, alkenylacyl, alkynylacyl, alkenyl
  • the polyurethanes can also be prepared by a two-step procedure where a prepolymer having terminally reactive polyisocyanate groups is prepared by reacting components (a) and (b) . The prepolymer is then reacted with the component (c) if present.
  • the polyurethanes may be further prepared by UV curing which involves the addition of a photoinitiator to components (a) , (b) and (c) followed by the application of UV radiation.
  • conventional polyurethane processing additives such as catalysts for example dibutyl tin dilaurate (DBTD), stannous oxide (SO), 1,8- diazabicyclo [5,4, 0] undec-7-ene (DABU) , 1, 3-diacetoxy- 1,1,3,3-tetrabutyldistannoxane (DTDS), 1,4-diaza- (2, 2, 2) - bicyclooctane (DABCO), N,N,N 1 ,N' -tetramethylbutanediamine (TMBD) and dimethyltin dilaurate (DMTD) ; antioxidants for example Irganox (Registered Trade Mark) ; radical inhibitors for example trisnonylphenyl phosphite (TNPP) ; stabilisers; lubricants for example Irgawax (Registered Trade Mark) ; dyes; pigments; inorganic and/or organic fillers,- and reinforcing materials; and initiator of
  • the polyurethanes of the present invention are particularly useful in preparing biomaterials and medical devices, articles or implants .
  • biomaterial refers to a material which is used in situations where it comes into contact with the cells and/or bodily fluids of living animals or humans .
  • the medical devices, articles or implants may include soft tissue implants designed to replace and augment tissues including breast tissue, testicular tissue, cartilage, muscle and any connective tissue apart from teeth and bone; orthopaedic joints or parts thereof including spinal discs and small joints; bone suture anchors; reconstructive facial surgery; controlled drug release devices; components in key hole surgery; biosensors; tools and accessories for insertion of medical devices, infusion and flow control devices; and urethral, neurological or vascular bulking agents.
  • Biological Stability The biological stability of the gels is achieved by the incorporation of large amount of silicon.
  • Rheology Both the natural feel and the form stability can be related to rheological factors. A good creep- recovery performance describes the feel or the elasticity.
  • the parameters of storage modulus (G' ) and loss modulus (G") as measured in frequency sweep measurement on a rheometer describe the form stability. G'>G" at low frequencies (0.01s '1 to Is "1 ) implies form stability.
  • Creep Recovery is tested using Haake RheoStress 1 Rheometer. After the initialisation process under compressed air atmosphere, the parallel plates are subjected to zero point measurement. The sample is loaded and the gap position set. The excess sample is trimmed and is ready for the experiment.
  • the creep recovery analysis is carried out at 37 0 C.
  • the sample is thermostated for 300s before the actual experiment starts to ensure temperature equilibrium.
  • the experiment is carried at a force of 10 Pa for a duration of 60s and from the plot of J (l/Pa, compliance) Vs t(s), the creep recovery results can be obtained.
  • Extractables The extractables in hexane as measured in the Soxhlet extraction technique over 24 hours shows an average value of around 50% for the silicone gels.
  • the extraction procedure involved five pieces of apparatus: condenser, soxhlet extractor tube, extraction thimble, 250 mL round-bottom flask and a heating mantle. The procedure was carried out as follow:
  • the approaches used in the formulation of gels involve initiation of cross-linking by the use of various functionalities of the reactants including unsaturated or double bonds in the PDMS molecule and then making the double bond reactive by using a ultraviolet light source or other techniques.
  • the reactants used for synthesising the gels include a di-isocyanate in the form of MDI and different hydroxyl terminated polyols of functionalities varying from 1 to 4.
  • the reactants are set out in Table 1 below: TABLE 1
  • EXAMPLE A This example illustrates the preparation of a statistical (1:2:1) mixture of ⁇ , ⁇ -bis (hydroxyethoxypropyl) polydimethylsiloxane (Ia) , ⁇ - (hydroxyethoxypropyl) - ⁇ - (6,7- dihydroxyethoxypropyl) polydimethylsiloxane (Ib) , and ⁇ , ⁇ -bis (6, 7- dihydroxyethoxypropyl) polydimethylsiloxane (Ic) .
  • reaction mixture was allowed to cool to room temperature and treated with 15g of activated carbon for 18 hours whilst stirring.
  • the reaction mixture was filtered through celite to remove the carbon.
  • the toluene was removed by rotary evaporator at 80 0 C under a reduced pressure of 20 torr.
  • This example illustrates the preparation of hydroxyethoxypropyl terminated 9.09%- (hydroxyethoxypropyl methyl siloxane) (dimethyl siloxane) copolymer (Id) .
  • 296.64g of D 4 , 30.67g of 1,3,5,7- tetramethylcyclotetrasiloxane, and 67.17g of TMDS were mixed in a glass bottle containing a magnetic stirrer bar.
  • 0.61g of trifluoromethanesulfonic acid was added to the mixture and the bottle sealed with " an air tight cap. The mixture was stirred vigorously for 18 hours at room temperature after which 1Og of sodium carbonate was added.
  • the bottle was resealed and stirred for 6 hours, after which the sodium carbonate was filtered off to give 384.5Og of hydride terminated (methylhydrosiloxane) (dimethylsiloxane) copolymer intermediate.
  • a three-neck IL round bottomed flask equipped with a water cooled condensed equipped with a silica gel drying tube, a 250-mL pressure compensating dropping funnel, and a thermometer were placed 384.5Og of the hydride terminated poly(methylhydrosiloxane) (dimethylsiloxane) copolymer given above and 20OmL of dry toluene.
  • the mixture was heated, whilst stirring, to 60 0 C.
  • the toluene was removed by rotary evaporator at 80 0 C under a reduced pressure of 20 torr.
  • the toluene was removed by rotary evaporator at 80 0 C under a reduced pressure of 20 torr.
  • the pale yellow product was treated with 1Og of activated carbon for 3 days to remove the residual colour.
  • This example illustrates the preparation of ⁇ , ⁇ ', ⁇ ", ⁇ ' 1 '- tetrakis- [ ⁇ [ (hydroxyethoxypropyldimethylsilyl) oxy]poly(dimethylsilyene) ]] silane (9Cl) (lib) .
  • 33.8Og of D 4 and 75.0Og of tetrakis (dimethylsiloxy) silane were mixed in a glass bottle containing a magnetic stirrer bar.
  • 0.128g of trifluoromethanesulfonic acid was added to the mixture and the bottle sealed with an air tight cap.
  • the mixture was stirred vigorously for 4 days at room temperature after which 1Og of sodium carbonate was added.
  • the bottle was resealed and stirred for 6 hours, after which the sodium carbonate was filtered off to give 91.92g of hydride terminated tetrakis (polydimethylsiloxane) silane intermediate.
  • the addition was made over a 30 minute period during which time the temperature of the mixture rose to 104 0 C after which the reaction mixture was maintained at 80 0 C for 1 hour. Silanic hydrogen content was checked by infrared spectroscopy. When no trace was detectable the reaction was considered to be complete.
  • the reaction mixture was allowed to cool to room temperature and treated with 1Og of activated carbon for 18 hours whilst stirring. The reaction mixture was filtered through celite to remove the carbon.
  • This example illustrates the preparation of hydroxyethoxypropyl terminated 3.55 %- ( methylmethacryloxypropyl methyl siloxane) (dimethyl siloxane) copolymer (Ie) .
  • the gels were synthesised using different processes: One Shot Process - All reactants of the gel were added and mixed together. Two Stage Process - The gel synthesis in this process occurred with the formation of a di-functional isocyanate terminated pre-polymer in the first stage followed by the addition of the hydroxyl terminated multifunctional polyols. Slow Addition Process - All the reactants of the gel were mixed in together but the polyols are added to the diisocycanate in a drop wise fashion.
  • UV Curing For the process of curing with ultra-violet light, a formulation containing an unsaturation in the polyol segment was prepared. A photoinitiator was added to the mixture and this in the presence of an externally supplied, long wavelength, ultraviolet radiation resulted in the formation of a cross linked gel.
  • MDI 4, 4' -Diphenylmethane diisocyanate
  • the gels were prepared in two steps; preparation of prepolymer with difunctional polyols to get desired NCO index (NCO/OH) followed by reaction of pre-polymer with multifunctional polyols to get desired stoichiometric imbalance "r" .
  • the PDMS (MW 2000) was degassed at 70 0 C under vacuum prior to synthesis.
  • Molten MDI was placed in a three necked round bottom flask which was fitted with a mechanical stirrer and nitrogen inlet. The flask was placed in an oil bath set at 70°C.
  • the degassed PDMS was added to MDI and was stirred by mechanical stirrer under a nitrogen atmosphere for 2 hours.
  • the temperature of the oil bath was increased to 8O 0 C.
  • the prepolymer stirred at 100 rpm under nitrogen atmosphere for 2 h.
  • the prepolymer was degassed for 1 hour under vacuum.
  • Prepolymers with 2% and 4% free NCO contents were made.
  • the free NCO% is based on the ratio of excess NCO functional group by the amount of prepolymer in weight percentage.
  • the excess NCO functional group is determined by the amount of excess MDI which contains 33.6% by weight NCO group.
  • the excess MDI is the amount which remains after reaction with hydroxyl terminated PDMS.
  • BDO 4-butanediol
  • BHTD bis-hydroxy butyl tetramethyldisiloxane
  • Voranol-2070 a mixture of polyol adducts viz. 1, 4-butanediol (BDO) /bis-hydroxy butyl tetramethyldisiloxane (BHTD), voranol-2070 and N, N, N' -tri (2-hydroxypropyl) -N' - hydroxyethylethylenediamine (Poly Q 40-800) stirring at 70 0 C.
  • the parts by weight (PBW) of the reactants in the formulations, stiochiometries, average functionality and extractables (%) are given in Table 3, 4 and 5 below.
  • the amount of multifunctional polyols is based on 10Og of prepolymer.
  • MDI 4, 4' -Diphenylmethane diisocyanate
  • MDI 4, 4' -Diphenylmethane diisocyanate
  • MDI 4, 4' -Diphenylmethane diisocyanate
  • UV-curing systems rely upon externally-supplied, long wavelength, ultraviolet radiation to produce free radicals within the material.
  • UV light does not usually have sufficient energy levels to interact with the reactive groups of the molecules and generate free radicals.
  • a photoinitiator is added to the formulation, which when exposed to UV of a specific wavelength, absorbs the UV light and produces free radicals which start the cross linking process and results in virtually instant polymerisation.
  • the reaction will only continue as long as the formulation is subjected to the UV light.
  • the molten MDI was placed in a three necked round bottom flask which was fitted with a mechanical stirrer and nitrogen inlet. The flask was placed in an oil bath set at 60 0 C. The synthesised hydroxyethoxypropyl terminated 3.55 %-
  • the molten MDI was placed in a three necked round bottom flask which was fitted with a mechanical stirrer and nitrogen inlet. The flask was placed in an oil bath set at 60 0 C.
  • the synthesised hydroxyethoxypropyl terminated 3.55 %- (methylmethacryloxypropyl methyl siloxane) (dimethyl siloxane) copolymer of Mw 1039 was added to MDI and stirred by mechanical stirrer under a nitrogen atmosphere for 2 h and was degassed for 1 h under vacuum.
  • PDMS 1000/2000 was then added to prepolyraer and allowed to mix using a shear mechanical stirrer for 4 min at 5000 rpm.
  • the polymer then accurately weighed for different formulation in a petri dish and mixed with required weight percentage (w/w) of photoinitiator (Irgacure 819) (varying percentage from 0.25 % - 2 % w/w) in ⁇ lml of toluene thoroughly using a spatula and placed in the UV chamber (home built) (OV lamp 5mW, 366 nm) for 48h to cure. Results are shown in Table 12 below.
  • Ratio of Test Material to Extraction Vehicle Material thickness less than 0.5 mm - ratio of 60 cm 2 :10 ml (based on the USP ratio 120 cm 2 :20 ml)
  • the extraction conditions shall attempt to exaggerate the clinical use conditions so as to define the potential toxicological hazard; however, they should not in any instance cause physical changes such as fusion or melting, which results in a decrease in the available surface area. A slight adherence of the pieces can be tolerated.
  • Negative Control high density polyethylene, will be prepared based on a ratio of 60 cm 2 :20 ml extraction vehicle. A single preparation of the material will be made, and will be extracted using the same conditions as described for the test article. Reagent Control: A single aliquot of the extraction vehicle without test material will be prepared using the same conditions as described for the test article.
  • Positive Control Current positive control material*, tin stabilized at polyvinylchoride, will be prepared based on a ratio of 60 cm 2 :20 ml extraction vehicle. A single preparation of the material will be made and extracted at 37 0 C for.24 hours. Serial dilutions will be prepared for an end-point titration procedure.
  • Test System and Justification Mammalian cell culture monolayer, L-929, mouse fibroblast cells, (ATCC CCL 1, NCTC Clone 929, of strain L, or equivalent source) , will be used. In vitro mammalian cell culture studies have been used historically to evaluate cytotoxicity of biomaterials and medical devices (Wilsnack, et al. , 1973) . Test System Management:
  • L-929, mouse fibroblast cells, (ATCC CCL 1, NCTC Clone 929, of strain L, or equivalent source) will be propagated and maintained in open we_lls containing single strength Minimum Essential Medium supplemented with 5% serum and 2% antibiotics (Ix MEM) in a gaseous environment of 5% carbon dioxide (CO 2 ) .
  • Ix MEM antibiotics
  • CO 2 carbon dioxide
  • 10 cm 2 wells will be seeded, labeled with passage number and date, and incubated at 37 0 C in 5% CO to obtain confluent monolayers of cells prior to use.
  • Aseptic procedures will be used in the handling of the cell cultures following approved Standard Operating Procedures.
  • Each culture well will be selected which contains a confluent cell monolayer.
  • the growth medium in triplicate cultures will be replaced with 2 ml of the test extract.
  • triplicate cultures will be replaced with 2 ml of the reagent control, negative control extract and the undiluted and each titer of the positive control.
  • Each well will be incubated at 37°C in 5% CO 2 for 48 hours.
  • the confluency of the monolayer will be recorded as (+) if present and (-) if absent.
  • the color of the test medium will be observed and compared to the negative control medium.
  • Each culture well will be evaluated for percent lysis and cellular characteristics using the following criteria:
  • the reagent control and the negative control must have a reactivity of none (grade 0) and the positive control must be a grade 3 or 4.
  • the test sample meets the requirements of the test if the biological response is less than or equal to grade 2 (mild) .
  • the test will be repeated if the controls do not perform as anticipated and/or if all three test wells do not yield the same conclusion.
  • USP United States Pharmacopeia
  • the objective of the maximization test in the guinea pig is to identify the potential for dermal sensitization.
  • Test Article The sample will be prepared as follows:
  • Ratio of test article extraction vehicle Material thickness less than 0.5mm - ratio of 120cm 2 20 ml
  • the vehicle used to prepare the extract will be prepared in the same manner as the extract (but without test article) serve as the control measure. Untreated skin will serve as an additional control reference for scoring dermal reactions during the challenge phase.
  • Species Guinea pig (Cavia porcellus) Strain: CrI: (HA) BR Source: Charles River Laboratories Sex: No particular gender is prescribed for this test. If females are used) they will be nulliparous and not pregnant.
  • Body Weight Range 300-500 grams at identification Age: Young adults Acclimation Period: Minimum 5 days Number of Animals: 15 (per extract) Identification Method: Ear punch
  • the Hartley albino guinea pig has been used historically for sensitization studies (Magnusson and Kilgman, 1970) .
  • the guinea pig is believed to be the most sensitive animal model for this type of study.
  • the susceptibility of the Hartley strain to a known sensitizing agent, l-chloro-2,4-dinitrobenzene (DNCB) has been substantiated with this method.
  • Fresh extracts will be prepared at each phase of the study as previously indicated (see Test Article) . If the test material is suitable for patching, a topical application of the test sample (2 cm x 2 cm patch) will be used at the challenge. The vehicle used to prepare the extract will be prepared in the same manner as the extract (but without test article) to serve as the control measure.
  • Control Animals a. 0.1 ml of 50:50 (v/v) mixture of Freund' s Complete Adjuvant (FCA) and the chosen vehicle b. 0.1 ml of vehicle c. 0.1 ml of a 1:1 mixture of the 50:50 (v/v) FCA and the vehicle
  • Test Animals a. 0.1 ml of 50:50 (v/v) mixture of FCA and the chosen vehicle b. 0.1 ml of test extract c. 0.1 ml of a 1:1 mixture of the 50:50 (v/v) FCA and the test extract
  • the injection sites will be clipped free of fur again and treated with 0.5 to 1 g of a 10% (w/w) sodium lauryl sulfate (SLS) suspension prepared by mixing the powdered SLS with petrolatum. The day following the SLS treatment, any remaining SLS residue will be gently wiped from the area with gauze. A 2 cm x 4 cm filter paper patch (3MM, Whatman) , saturated with 0.3 ml of the extract preparation or vehicle, will be applied over the same injection area and secured with a nonreactive tape. The trunk of each animal will then be wrapped snugly with an elastic band for 48 hours ( ⁇ 2 hours) .
  • SLS sodium lauryl sulfate
  • the fur will be clipped from the sides and flanks of all guinea pigs.
  • a nonwoven cotton disk backed by a flexible chamber e.g. Hill Top Chamber ®
  • semiocclusive hypoallergenic tape will be saturated with 0.3 ml of freshly prepared test material extract and applied to the right flank or dorsum of each animal.
  • the vehicle control will be patched to the left flank or dorsum of each animal.
  • An approximate 2 cm x 2 cm section of test material itself (if appropriate) will be applied to the right flank.
  • the trunk of each animal will be wrapped for 24 hours ( ⁇ 2 hours) . At patch removal the sites will be wiped with gauze.
  • the challenged sites and surrounding area will be shaved.
  • the sites will be examined for signs of ahy irritation or sensitization reaction, as indicated by erythema and edema at a minimum of 2 hours and a maximum of 4 hours following the shave and at 48 ( ⁇ 2 hours) and 72 ( ⁇ 2 hours) hours after removal of the dressings.
  • each site Prior to scoring, each site will be wiped gently with a 35% isopropyl alcohol gauze sponge.
  • the animals may be rechallenged with a fresh test extract and vehicle control approximately 7 days after the first challenge patch application.
  • the rechallenge will be conducted in the same manner as the challenge but at virgin sites on the opposite flank. After the test is completed, all animals will be handled in accordance with approved procedures.
  • Control conditions are (1) the vehicle control solution on the test animals and (2) the test extract, control solution and biomaterial (if applied) on the control animals.
  • FCA and occlusive dressings may lower the threshold level for skin irritation.
  • a rechallenge may be conducted.
  • the rechallenge will be conducted approximately 7 days after the first challenge at virgin sites on the opposite flank of the animals. Absence of dermal response at rechallenge may nullify earlier findings. Recurring observations in at least one of the same animals verify earlier findings.
  • EXAMPLE 8 ACUTE INTRACUTANEOUS REACTIVITY STUDY IN THE RABBIT
  • the objective of this study is to evaluate the local dermal irritant effects of leachables extracted from the test article following intracutaneous injection in rabbits. This study will be based on the requirements of the International Organization for Standardisation 10993 :
  • Test Article The sample will be prepared as follows:
  • Control Article Reagent controls (extraction vehicle without test material) will be prepared in the same way and at the same time as the test extracts.
  • Body Weight Range 2.0 kg or greater at selection Age: Young adults
  • the intracutaneous injection test in rabbits is specified in the current ISO testing standards and has been used historically to evaluate biomaterial extracts.
  • each rabbit will be weighed and clipped free of fur from the back and both sides of the spinal column to yield a sufficient injection area.
  • the clipped area of the back will be wiped with a 70% alcohol soaked gauze pad just before injection and allowed to dry. Due to concern with the crowding and subsequent obscuring of injection sites, the test and control sites will not be cranial and caudal on the same side of the back as defined in the ISO standards.
  • Each test extract will be administered in five intracutaneous injections of 0.2 ml each on the right side of each rabbit's back. Five reagent control injections will be injected similarly on the left side of the back. No more than two test extracts and the corresponding reagent controls will be injected into each animal. Injections will be about 2 cm apart. The appearance of the injection sites will be noted immediately after injection.
  • the erythema and edema scores obtained at each time interval will be added together and divided by the total number of observations . This calculation will be conducted separately for each test extract and reagent control. The score for the reagent control will be subtracted from the score for the test extract to obtain the Primary Irritation Score. The Primary Irritation Score of each animal will be added together and divided by the total number of animals. The value obtained is the Primary Irritation Index (PII) .
  • the Primary Irritation Index is characterized by number and description as follows: 0-0.4 (negligible) , 0.5-1.9 (slight) , 2.0-4.9 (moderate), 5.0-8.0 (severe) . If the response in the initial test is equivocal, additional testing may be necessary. Any adverse reaction noted in the test extract will be compared to the corresponding reagent control.
  • the final report will include a description of the methods employed, individual dermal scores for each test and control injection site, and the assessment of the results (Primary Irritation Scores and the Primary Irritation Index) .
  • Test article and reagent control preparation data dates of relevant activities (such as the study initiation and completion) , the appearance of each injection site immediately after injection, individual dermal scores at 24, 48 and 72 hours, the Primary Irritation Score, and the Primary Irritation Index will be recorded.
  • USP United States Pharmacopeia
  • the objective of this study is to evaluate acute systemic toxicity of leachables extracted from the test article following a single intravenous or intraperitoneal injection in mice. This study will be conducted in accordance with the methods recommended by the International Organization for Standardization 10993: Biological Evaluation of Medical Devices, Part II: Tests for Systemic Toxicity.
  • the sample will be prepared as follows:
  • Ratio of test article to extraction vehicle — Material thickness less than 0.5 mm - ratio of 120 cm 2 :20 ml
  • Blank controls extraction vehicle without test material
  • Body Weight Range 17-23 grams at injection Age: No particular age is prescribed for this test
  • mice have historically been used to evaluate biomaterial extracts.
  • the use of albino mice injected with a single intravenous (iV) or intraperitoneal (IP) dose of test article extract or control blank have been suggested by the current USP and ISO for evaluation of medical plastics.
  • mice Prior to dosing, the mice will be identified and weighed. Five animals will each be injected with the appropriate test extract at a dose of 50 ml/kg (SC, AS, vegetable oil) or 10 g/kg (PEG) . Five mice will be similarly injected with the corresponding extraction vehicles. The SC and AS will be injected intravenously via the lateral tail vein while the PEG and vegetable oil will be injected intraperitoneally. Mice will be observed for adverse reactions immediately after dosing, and at 4, 24, 48 and 72 hours after injection. Following the 72 hour observation, the animals will be weighed. Any animal found dead will be subjected to a gross necropsy of the viscera. After the test is completed, all animals will be handled in accordance with approved procedures.
  • test sample meets the test requirements. If two or more mice die, or if abnormal behavior such as convulsions or prostration occurs in two or more mice, or if body weight loss greater than 2 grams occurs in three or more mice, the test sample does not meet the test requirements. If any mice treated with the test extract show only slight signs of toxicity and not more than one mouse shows gross signs of toxicity or dies, a ten mouse retest may be required. If all ten mice treated with the test extract on the repeat test show no significant reaction greater than the control mice, then the test sample meets the current test requirements.
  • the final report will include a description of the methods employed, individual body weights, and any observations.
  • USP United States Pharmacopeia
  • the objective of this study is to evaluate the subchronic systemic toxicity of leachables extracted from the test article following repeated intravenous injections in rats for a period of 14 consecutive days .
  • the extracts will be used within 24 hours of completion of the extraction process or as directed by the sponsor.
  • a vehicle control (SC without test article) will be prepared in the same way and at the same time as the test extract.
  • a single group of common control animals may be dosed when multiple test articles are evaluated at the same time.
  • Test System Species: Rat (Rat us norvigicus)
  • Body Weight Range No particular weight range is prescribed for this study, however, individual pretreatment body weights will be within 20% of the group mean for each sex Age: Approximately 6 to 8 weeks old at first treatment
  • rats will be weighed and randomly assigned to each treatment group. Ten rats (five male, five female) will receive an injection of the test article extract once each day for 14 consecutive days. The test extract will be injected via the lateral tail vein at a dose of 10.0 ml/kg. The individual daily dose will be based on the weight of each animal on the first dose day of each week. The appropriate dose volume will be calculated to the nearest 0.1 ml. An appropriate gauge needle attached to a disposable syringe will be used to deliver the injection. The injection rate will be approximately 1.0 ml/10 seconds. Animals will be dosed at approximately the same time each day. Ten rats (five male, five female) will be similarly injected with the control blank. The first day of dosing will be designated as day 1.
  • Body weights will be recorded to the nearest whole gram prior to the first dose, on day 8, 14 (pre-fasted weight) and 15 (fasted weight) .
  • the animals At the end of the workday on day 14, the animals will be weighed and food will be withheld for a maximum of 20 hours.
  • the animals On day 15, the animals will be weighed and then anesthetized by intraperitoneal injection of ketamine hydrochloride and xylazine (88 mg/kg + 12 mg/kg) dosed at 3.0 ml/kg.
  • the abdomen will be opened and a blood specimen will be collected from the posterior vena cava.
  • the blood specimens will be forwarded to a contract laboratory for complete blood cell count with differential and clinical chemistry analyses. Rats will be euthanized by exsanguination while anesthetized.
  • a macroscopic observation of the viscera will be conducted.
  • the following organs will be removed: heart, lungs, liver, spleen, thymus, kidneys (2), adrenal glands (2) , mesenteric lymph nodes, submandibular lymph nodes, gonads (2) and any tissue with visible gross lesions.
  • the liver, spleen, thymus, kidneys, adrenal glands and gonads will be weighed. Paired organs will be weighed together.
  • the tissues will be preserved in 10% neutral buffered formalin (NBF) until further processing. The carcasses will be discarded.
  • NBF neutral buffered formalin
  • Body weight data, organ weight data, organ/body weight ratios, hematology and clinical chemistry data will be evaluated statistically. Pre-fasted body weights will be used to determine weight gain and the fasted body weights will be used to determine anesthetic dosages at termination and organ/body weight ratios . Descriptive statistics and group comparisons of data will be accomplished using a validated statistical software package. After screening the data for normality and equal variance, the appropriate parametric or nonparametric tests will be performed. Normally distributed data with equal variance will be considered parametric and evaluated using an ⁇ unpaired t-test" for comparison of two groups. Jf data is nonparametric, the "Mann-Whitney Rank Sum Test" is used for two group comparisons.
  • the data to be analyzed will include: body weight, organ weight and hematological parameters.
  • the treatment groups will be used as variables. Calculations resulting in probability (p) values less than 0,05 will be considered statistically significant. If directed by the evaluating pathologist, statistical evaluation of pathologic findings may be conducted.
  • Clinical signs of systemic illness or death will not be analyzed statistically unless a rationale (such as frequently observed clinical signs or emergence of a pattern) for such analysis is apparent from these data. If the incidence of occurrence of any one or more observations is sufficient to warrant analysis, a chisquare test will be employed.
  • the final report will include a description of the methods employed, clinical observations, body weight data, hematology and clinical chemistry data, organ weight data, organ/body weight ratios, necropsy findings, the microscopic evaluation in the histopathology report, the statistical analyses and conclusions .
  • EXAMPLE 11 GENOTOXICITY: BACTERIAL REVERSE MUTATION STUDY
  • the purpose of the study is to evaluate whether an extract of the test material or a solubilized material will cause mutagenic changes in a tryptophan-dependent strain of Escherichia, coli or in one or more strains of histidine-dependent Salmonella typhimurium in the presence or absence of 59 metabolic activation.
  • the Bacterial Reverse Mutation Study will be used as a rapid screening procedure for the determination of inutagenic and potential carcinogenic hazards and should be used in conjunction with other tests that characterize potential genotoxicity properties. This study will be based on OECD guidelines and the requirements of the International Organization for Standardization: Biological Evaluation of Medical Devices - Part 3 : Tests for Genotoxicity, Carcinogenicity and Reproductive Toxicity.
  • the sample will be prepared as follows :
  • One gram of the sample will be transferred to a 10 ml volumetric flask.
  • Various sized flasks may be used to accommodate nature of test material utilizing 100 mg/ml or 10% w/v.
  • Appropriate vehicle (specified below) will be added (q.s.) to the 10 ml (or appropriate) demarcation to achieve 100 mg/ml or a 10% (w/v) solution of the material.
  • One milliliter of the sample will be transferred to a 10 ml volumetric flask.
  • Various sized flasks may be used to accommodate nature of test material utilizing 100 mg/ml or 10% v/v.
  • Appropriate vehicle (specified below) will be added (q.s.) to the 10 ml (or appropriate) demarcation to achieve 100 mg/ml or a 10% (v/v) solution of the material.
  • Each S. typhimurium tester strain contains a specific mutation in the histidine operon and other mutations that increase their ability to detect mutagens.
  • the E. coli strain contains a mutation in the tryptophan operon and a deletion in the uvrA gene.
  • These genetically altered S. typhimurium strains (TA9S, TAlOO, TA1535, and TA1537) and E. coli strain (WP2uvrA) cannot grow in the absence of histidine or tryptophan, respectively. When placed in a histidine-free (for S.
  • tryptophan-free (for E coli) medium only those cells which mutate spontaneously back to their wild type state (histidine independent by manufacturing their own histidine, or tryptophan independent by manufacturing their own iryptophan) are able to form colonies .
  • the spontaneous mutation rate (or reversion rate) for any one strain is relatively constant, but if a mutagen is added to the test system, the mutation rate is significantly increased.
  • Tester Strain Mutations/Genotypic Relevance S. typhimurium TA98 hisD3O52, rfa, uvrB, frameshift, pKMIOl
  • rfa causes partial loss of the lipopolysaccharide wall which increases permeability of the cell to large molecules (i.e., crystal violet inhibition)
  • uvrB or uvrA deficient DNA excision - repair system
  • pKMIOl plasmid confers ampicillin resistance (R- factor) and enhances sensitivity to mutagens
  • Aroclor 1254 - induced rat liver will be used as metabolic activation.
  • the material is prepared from male, Sprague Dawley rats. The rats are induced with one intraperitoneal injection of Aroclor 1254 (500 mg/ml) 5 days prior to sacrifice.
  • the S9 homogenate is purchased from Organon Teknika Corporation, Box 15969, Durham, NC 27704-0969. Just prior to use, the S9 homogenate will be mixed with a buffer containing 0.4 M MgCl 2 /65 M KCl, 1.0 M Glucose-6-phosphate, 0.1 M NADP, 0.2 M sodium phosphate buffer and sterile water.
  • Cultures of Salmonella typhimurium, TA98, TAlOO, TA1535 and TA1537, and Escherichia coli, WP2uvrA will be inoculated to individual Erlenmeyer flasks containing oxoid broth.
  • the inoculated broth cultures will be incubated at 37 ⁇ 2 0 C in an incubator shaker operating at 115-125 rpm for 10-12 hours.
  • Negative control (vehicle without test material) will be utilized for each tester strain with and without S9 activation.
  • a known mutagen, Dexon (paradimethylaminobenzene diazosulfonic acid sodium salt) will be used as a positive control to demonstrate that tester strains TA98, TAlOO 7 and TA1537 are sensitive to mutation to the wild type state.
  • For tester strain TA 1535 sodium azide will be used as a positive control.
  • For tester strain TAlOO 2- aminofluorene will be used as a positive control.
  • For tester strain WP2uvrA, 2-aminoanthracene and methylmethane-sulfonate will be used as positive controls.
  • metabolic activation is only required with 2- aminofluorene and 2-aminoanthracene to induce mutagenic results, all positive controls will be tested with and without S9 homogenate.
  • Strain Characteristics and Strain Standard Plate Counts Strain characteristics will be verified and viable counts will be determined.
  • the extract (s) or solubilized material (s) and negative control (s) will be evaluated by a spot plate technique modeled after the antimicrobial zone of inhibition test. This screen is used to evaluate extract or solution concentrations for toxicity which are noninhibitory to the Salmonella strains and the E. coli strain.
  • Separate tubes containing 2 ml of molten top agar supplemented with histidine-biotin (for S. typhimurium) or with tryptophan (for E. coli) will be inoculated with 0.1 ml of culture for each of the five tester strains. After mixing, the agar will be poured across the surface of separate Minimal E plates labeled with lab number, appropriate tester strain, and dose level (when necessary) . Once the agar solidifies, sterile filter discs will be placed in the center of the plates. A 0.1 ml aliquot of the extract or solubilized material will be added to the filter discs on each of the labeled plates. Parallel testing will be conducted with a negative control. To demonstrate a positive zone of inhibition, 1OX stock Dexon will be used.
  • the plates will be incubated at 37 ⁇ 2°C for 2-3 days. Following the incubation period, the zone of growth inhibition will be recorded. If significant inhibition of the background lawn occurs, the extract or solubilized material concentration will be adjusted by preparing one or more dilutions and repeating the inhibition screen to find a nontoxic level.
  • Histidine-free media plates for S. typhimurium
  • tryptophan-free media plates for JB. coli
  • the plates will be incubated at 37 + 2°C for 2-3 days. After the incubation period, the revertant colonies on each plate (test, negative and positive) will be counted and recorded. The mean number of revertants will be calculated.
  • the mean number of revertants of the triplicate test plates will be compared to the mean number of revertants of the triplicate negative control plates for each of the five tester strains employed.
  • the means obtained for the positive controls are used as points of reference.
  • any apparent "positive response” will be confirmed by demonstrating a dose-response relationship using three nontoxic dose levels of the test material. There should be a range of concentrations that produce a linear dose response. In the event linearity cannot be established, the assay will be repeated with an appropriate change in dose levels. A test material will be judged mutagenic if it causes a dose-related increase in the number of revertants over a minimum of two increasing dose concentrations.
  • Tester strains TA98, TAlOO, TA1535, and TA1537) must exhibit sensitivity to crystal violet [rfa mutation) , and ultraviolet light ⁇ uvrB) , and must exhibit no growth on biotin plates, and growth on histidine-biotin plates.
  • Tester strains TA98 and TA 100 must exhibit resistance to ampicillin (R- factor) ; tester strains TA1535 and TA1537 must exhibit sensitivity to ampicillin.
  • Tester strain WP2uvrA must exhibit sensitivity to ultraviolet light, no growth on tryptophan deficient plates, growth on tryptophan supplemented media and sensitivity to ampicillin.
  • a viable count on the working culture suspensions for each tester strain should not be less than 1 x 10 CFU/ml.
  • the negative control results of each tester strain will exhibit a characteristic number of spontaneous revertants. Spontaneous reversion rates may vary, but should be consistent with the ranges specified (see Table below) . The Table is meant as a guideline only. Negative control results for tester strains may fall outside of the range listed. In such an instance, the results should be evaluated with caution.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Prostheses (AREA)
EP05791328.7A 2004-09-29 2005-09-28 Gele Active EP1799739B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004905628A AU2004905628A0 (en) 2004-09-29 Polyurethanes
PCT/AU2005/001491 WO2006034547A1 (en) 2004-09-29 2005-09-28 Gels

Publications (3)

Publication Number Publication Date
EP1799739A1 true EP1799739A1 (de) 2007-06-27
EP1799739A4 EP1799739A4 (de) 2010-04-07
EP1799739B1 EP1799739B1 (de) 2014-02-12

Family

ID=36118511

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05791328.7A Active EP1799739B1 (de) 2004-09-29 2005-09-28 Gele

Country Status (7)

Country Link
US (1) US8207245B2 (de)
EP (1) EP1799739B1 (de)
JP (2) JP2008514314A (de)
CN (1) CN101039982B (de)
BR (1) BRPI0515934B8 (de)
ES (1) ES2452018T3 (de)
WO (1) WO2006034547A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034547A1 (en) 2004-09-29 2006-04-06 Aortech Biomaterials Pty Ltd Gels
WO2007112485A1 (en) 2006-03-31 2007-10-11 Aortech Biomaterials Pty Ltd Biostable polyurethanes
JP2009533190A (ja) 2006-04-20 2009-09-17 エイオーテク バイオマテリアルズ プロプライアタリー リミティド ゲル
JP2010505557A (ja) * 2006-10-10 2010-02-25 エイオーテク バイオマテリアルズ プロプライアタリー リミティド 軟組織インプラント
US8882832B2 (en) 2011-07-29 2014-11-11 Aortech International Plc Implantable prosthesis
PT2556806E (pt) * 2011-08-11 2016-06-02 Polytech Health&Aesthetics Gmbh Prótese médica implantável
TWI488892B (zh) * 2011-12-29 2015-06-21 Pegavision Corp 親水性矽膠預聚物之製造方法
TWI434865B (zh) 2011-12-29 2014-04-21 Pegavision Corp 親水有機矽高聚物之製造方法
CN103183803B (zh) * 2011-12-29 2015-02-11 晶硕光学股份有限公司 亲水性硅胶预聚物的制造方法
CN103183830B (zh) * 2011-12-29 2015-06-10 晶硕光学股份有限公司 亲水有机硅高聚物的制造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863627A (en) * 1997-08-26 1999-01-26 Cardiotech International, Inc. Hydrolytically-and proteolytically-stable polycarbonate polyurethane silicone copolymers
US20030018156A1 (en) * 1996-09-23 2003-01-23 Cardiac Crc Nominees Pty Ltd. Polysiloxane-containing polyurethane elastomeric compositions
US20040054080A1 (en) * 2002-09-17 2004-03-18 Benz Michael Eric Compounds containing silicon-containing groups, medical devices, and methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1266496B (de) * 1963-06-15 1968-04-18 Bayer Ag Organopolysiloxan-Emulsionen
JPS62224051A (ja) 1986-03-26 1987-10-02 Nitto Electric Ind Co Ltd 樹脂封止半導体装置
DE4023556A1 (de) * 1990-07-25 1992-01-30 Goldschmidt Ag Th Haertbare epoxygruppen aufweisende organopolysiloxane, verfahren zu ihrer herstellung und ihre verwendung als haertbare beschichtungsmittel mit abhaesiven eigenschaften
EP0559739B1 (de) 1990-11-27 1998-03-18 Commonwealth Scientific And Industrial Research Organisation A process for the production of polyalkylenoxide
JPH06510811A (ja) 1991-09-12 1994-12-01 ボシュ　アンド　ロム　インコーポレイテッド ぬれ性のシリコーンヒドロゲル組成物および方法
CA2116849C (en) * 1991-09-12 2001-06-12 Yu-Chin Lai Wettable silicone hydrogel compositions and methods
US5336797A (en) * 1992-12-30 1994-08-09 Bausch & Lomb Incorporated Siloxane macromonomers
AUPO700297A0 (en) 1997-05-26 1997-06-19 Cardiac Crc Nominees Pty Limited Silicon-based polycarbonates
US7052131B2 (en) * 2001-09-10 2006-05-30 J&J Vision Care, Inc. Biomedical devices containing internal wetting agents
AUPP268898A0 (en) 1998-03-31 1998-04-23 Cardiac Crc Nominees Pty Limited High modulus polyurethane compositions
AUPP991799A0 (en) 1999-04-23 1999-05-20 Cardiac Crc Nominees Pty Limited Siloxane-containing polyurethane-urea compositions
AUPQ170799A0 (en) * 1999-07-20 1999-08-12 Cardiac Crc Nominees Pty Limited Shape memory polyurethane or polyurethane-urea polymers
DE60014812T2 (de) 1999-09-02 2006-03-09 Dow Corning Corp., Midland Faserbehandlungsmittel enthaltend Siloxane mit Amin-, Polyol- und Amid-Funktionalität
DE10119583A1 (de) 2001-04-19 2002-10-24 Getzner Werkstoffe Ges M B H Siloxan-Elastomer
AU2002950469A0 (en) 2002-07-30 2002-09-12 Commonwealth Scientific And Industrial Research Organisation Improved biomedical compositions
CN2574279Y (zh) 2002-10-09 2003-09-17 刘玉环 电池充电电路
AU2003295249A1 (en) 2002-12-09 2004-06-30 Suprapolix B.V. Siloxane polymers with quadruple hydrogen bonding units
US20050043585A1 (en) * 2003-01-03 2005-02-24 Arindam Datta Reticulated elastomeric matrices, their manufacture and use in implantable devices
US8097565B2 (en) 2003-06-30 2012-01-17 Johnson & Johnson Vision Care, Inc. Silicone hydrogels having consistent concentrations of multi-functional polysiloxanes
WO2006034547A1 (en) 2004-09-29 2006-04-06 Aortech Biomaterials Pty Ltd Gels
AU2005289374B2 (en) 2004-09-29 2011-07-14 Aortech International Plc Gels
US7279538B2 (en) * 2005-04-01 2007-10-09 Bausch & Lomb Incorporated Aromatic-based polysiloxane prepolymers and ophthalmic devices produced therefrom
JP2009533190A (ja) * 2006-04-20 2009-09-17 エイオーテク バイオマテリアルズ プロプライアタリー リミティド ゲル

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030018156A1 (en) * 1996-09-23 2003-01-23 Cardiac Crc Nominees Pty Ltd. Polysiloxane-containing polyurethane elastomeric compositions
US5863627A (en) * 1997-08-26 1999-01-26 Cardiotech International, Inc. Hydrolytically-and proteolytically-stable polycarbonate polyurethane silicone copolymers
US20040054080A1 (en) * 2002-09-17 2004-03-18 Benz Michael Eric Compounds containing silicon-containing groups, medical devices, and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006034547A1 *

Also Published As

Publication number Publication date
CN101039982B (zh) 2011-06-15
US20080293844A1 (en) 2008-11-27
EP1799739A4 (de) 2010-04-07
WO2006034547A1 (en) 2006-04-06
BRPI0515934A (pt) 2008-08-12
BRPI0515934B8 (pt) 2021-07-27
JP2008514314A (ja) 2008-05-08
JP2013177601A (ja) 2013-09-09
EP1799739B1 (de) 2014-02-12
BRPI0515934B1 (pt) 2018-04-10
ES2452018T3 (es) 2014-03-31
CN101039982A (zh) 2007-09-19
US8207245B2 (en) 2012-06-26

Similar Documents

Publication Publication Date Title
US10597497B2 (en) Gels
EP1799739B1 (de) Gele
CA3003063C (en) Polyurethane/urea materials
AU2005289374B2 (en) Gels
US12129331B2 (en) Polyurethane/urea materials

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070424

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: VENKATARAMANI, SRIRAM

Inventor name: THANH NHAN, TRANG

Inventor name: MEHRABI, MANSOUR

Inventor name: BOWN, MARK

Inventor name: PADSALGIKAR, AJAY

A4 Supplementary search report drawn up and despatched

Effective date: 20100304

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 27/16 20060101ALI20100226BHEP

Ipc: C07F 7/18 20060101ALI20100226BHEP

Ipc: C08G 18/32 20060101ALI20100226BHEP

Ipc: A61L 27/18 20060101ALI20100226BHEP

Ipc: C07F 7/08 20060101ALI20100226BHEP

Ipc: C08G 77/442 20060101ALI20100226BHEP

Ipc: C08G 77/445 20060101ALI20100226BHEP

Ipc: C08G 77/458 20060101AFI20100226BHEP

Ipc: C08F 30/08 20060101ALI20100226BHEP

Ipc: C08G 77/46 20060101ALI20100226BHEP

Ipc: C08G 18/61 20060101ALI20100226BHEP

Ipc: A61L 27/52 20060101ALI20100226BHEP

17Q First examination report despatched

Effective date: 20100622

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AORTECH INTERNATIONAL PLC

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130816

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 652139

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005042689

Country of ref document: DE

Effective date: 20140327

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2452018

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140331

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140212

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 652139

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140212

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140612

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005042689

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20141113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005042689

Country of ref document: DE

Effective date: 20141113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140928

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050928

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140212

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20160926

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20160923

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170928

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20181017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170929

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602005042689

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240926

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240930

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240926

Year of fee payment: 20